or Try an Advanced Search...

    Technical Analysis for PHVS - Pharvaris N.V.

    Grade Last Price % Change Price Change
    C 20.85 -7.82% -1.77
    PHVS closed down 7.82 percent on Wednesday, May 8, 2024, on 36 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical PHVS trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Fell Below 200 DMA Bearish 0.00%
    MACD Bearish Centerline Cross Bearish 0.00%
    50 DMA Resistance Bearish -7.82%
    20 DMA Support Bullish -7.82%
    200 DMA Support Bullish -7.82%
    Doji - Bullish? Reversal -7.82%
    Earnings Movers Other -7.82%
    50 DMA Resistance Bearish -8.07%
    20 DMA Support Bullish -8.07%
    Older End-of-Day Signals for PHVS ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 19 hours ago
    Possible NR7 about 19 hours ago
    Fell Below Previous Day's Low about 20 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    Down 3% about 21 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    PHVS Chart by TradingView
    Basic chart:

    Profile

    Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Life Sciences Health Sciences Rare Diseases Angioedema Hereditary Angioedema Complement Deficiency

    Is PHVS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
    Apr 12 Pharvaris files for automatic mixed securities shelf
    Apr 12 Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
    Apr 10 Pharvaris reports Q4 results
    Apr 10 Pharvaris appoints David Nassif as chief financial officer
    Apr 10 Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    Apr 10 Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
    Apr 4 Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
    Mar 18 Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
    Mar 6 Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
    See more PHVS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 33.0
    52 Week Low 7.93
    Average Volume 75,976
    200-Day Moving Average 22.20
    50-Day Moving Average 22.99
    20-Day Moving Average 21.93
    10-Day Moving Average 23.10
    Average True Range 2.08
    RSI (14) 41.52
    ADX 11.88
    +DI 16.73
    -DI 21.58
    Chandelier Exit (Long, 3 ATRs) 19.27
    Chandelier Exit (Short, 3 ATRs) 23.80
    Upper Bollinger Bands 25.12
    Lower Bollinger Band 18.73
    Percent B (%b) 0.33
    BandWidth 29.13
    MACD Line -0.09
    MACD Signal Line -0.14
    MACD Histogram 0.0532
    Fundamentals Value
    Market Cap 1.09 Billion
    Num Shares 52.1 Million
    EPS -3.27
    Price-to-Earnings (P/E) Ratio -6.38
    Price-to-Sales 0.00
    Price-to-Book 9.11
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 23.83
    Resistance 3 (R3) 24.07 23.32 23.33
    Resistance 2 (R2) 23.32 22.57 23.20 23.17
    Resistance 1 (R1) 22.09 22.10 21.71 21.84 23.00
    Pivot Point 21.34 21.34 21.15 21.22 21.34
    Support 1 (S1) 20.10 20.58 19.73 19.86 18.70
    Support 2 (S2) 19.35 20.11 19.23 18.53
    Support 3 (S3) 18.12 19.35 18.37
    Support 4 (S4) 17.87